Phaseline

Companies › CSL Behring

CSL Behring: clinical trials, targets and expected readouts

12 active drug programs in 20 registered trials: 8 Phase 2, 6 Phase 3, 5 Phase 4, 1 Phase 1; Hematology, Gastroenterology, Metabolic and endocrine, Cardiovascular; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IgPro10 (Privigen)
Normal human immunoglobulin G (IVIG)
–Phase 4Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Dec 2029
.Alpha.1-Proteinase Inhibitor Human (CE1226)
Leukocyte elastase inhibitor
ELANEPhase 4Alpha1 Antitrypsin Deficiency; Eosinophilic EsophagitisSep 2033
Prothrombin Complex Concentrate (BE1116)
Coagulation factor VII exogenous protein; Vitamin K-dependent protein S exogenous protein; Vitamin K-dependent protein C exogenous protein
F7, PROS1, PROC, F9, F2Phase 3Complex Cardiovascular Surgery With Cardiopulmonary Bypass; Cardiac Valve Disease; Hemophilia; Liver CirrhosisApr 2027
CSL511 Fibrinogen concentrate (human)
Fibrinogen (clotting factor I) replacement
FGAPhase 3Acquired Fibrinogen DeficiencyJun 2027
Etranacogene Dezaparvovec (CSL222)
Coagulation factor IX exogenous protein
F9Phase 3Hemophilia BOct 2028
IgPro20
Immune globulin replacement therapy
–Phase 3Secondary Immune Deficiency; Multiple MyelomaSep 2029
Lonoctocog Alfa
Coagulation factor VIII exogenous protein
F8Phase 3Congenital Hemophilia A–
Clazakizumab (CSL300)
Interleukin-6 inhibitor
IL6Phase 2End Stage Kidney Disease; End Stage Kidney Disease (ESKD); COVID-19 InfectionAug 2027
CSL889
Human hemopexin
HPXPhase 2Sickle Cell Disease Vaso-occlusive CrisisOct 2027
Vamifeport
Ferroportin stabilizer
FPN1Phase 2Homeostatic Iron Regulator Gene-related Hereditary HemochromatosisApr 2028
Anumigilimab (CSL324)
Granulocyte colony stimulating factor receptor antagonist
CSF3RPhase 2Sickle Cell DiseaseAug 2028
CSL787
human normal immunoglobulin G (IgG) inhalation solution
–Phase 2Non-cystic Fibrosis BronchiectasisMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04494724Clazakizumab (CSL300)Phase 2COVID-19 InfectionInfectious diseaseDec 2020
NCT06738485Lonoctocog AlfaPhase 3Congenital Hemophilia AHematologySep 2026
NCT06144125Prothrombin Complex Concentrate (BE1116)Phase 4Cardiac Valve DiseaseHematologySep 2026
NCT07406139Prothrombin Complex Concentrate (BE1116)Phase 4HemophiliaHematologyDec 2026
NCT05667805Prothrombin Complex Concentrate (BE1116)Phase 4Liver CirrhosisGastroenterologyJan 2027
NCT05485155.Alpha.1-Proteinase Inhibitor Human (CE1226)Phase 2Eosinophilic EsophagitisGastroenterologyJan 2027
NCT07094087Prothrombin Complex Concentrate (BE1116)Phase 3Complex Cardiovascular Surgery With Cardiopulmonary BypassCardiovascularApr 2027
NCT06617897CSL511 Fibrinogen concentrate (human)Phase 3Acquired Fibrinogen DeficiencyHematologyJun 2027
NCT07619820Clazakizumab (CSL300)Phase 1End Stage Kidney Disease (ESKD)CardiovascularAug 2027
NCT06699849CSL889Phase 2Sickle Cell Disease Vaso-occlusive CrisisHematologyOct 2027
NCT07332091VamifeportPhase 2Homeostatic Iron Regulator Gene-related Hereditary HemochromatosisMetabolic and endocrineApr 2028
NCT07224360Anumigilimab (CSL324)Phase 2Sickle Cell DiseaseHematologyAug 2028
NCT06003387Etranacogene Dezaparvovec (CSL222)Phase 3Hemophilia BHematologyOct 2028
NCT07048262CSL787Phase 2Non-cystic Fibrosis BronchiectasisRespiratoryMay 2029
NCT06976476IgPro20Phase 2Multiple MyelomaOncologyMay 2029
NCT05485961Clazakizumab (CSL300)Phase 2End Stage Kidney DiseaseCardiovascularMay 2029
NCT07648264IgPro20Phase 3Secondary Immune DeficiencyOncologySep 2029
NCT03684018IgPro10 (Privigen)Phase 4Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NeurologyDec 2029
NCT07326592.Alpha.1-Proteinase Inhibitor Human (CE1226)Phase 4Alpha1 Antitrypsin DeficiencyMetabolic and endocrineSep 2033
NCT07080905Etranacogene Dezaparvovec (CSL222)Phase 3Hemophilia BHematologyOct 2033

From the company's SEC filings

Complete response letters from FDA

Targets

F9 (2) ELANE (1) IL6 (1) FGA (1) CSF3R (1) FPN1 (1) HPX (1) F7 (1) PROS1 (1) PROC (1) F2 (1) F8 (1)

Companies with the same targets

BioMarin Pharmaceutical Pfizer Roche Shanghai Xinzhi BioMed IntraBio Baxalta now part of Shire Biocad Regeneron Pharmaceuticals Onchilles Pharma Grifols Therapeutics

Companies built like this

Grand Shuyang Life Sciences (Chengdu) Chongqing Peg-Bio Biopharm Kedrion Longbio Pharma Keymed Biosciences Co.Ltd

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.